How the answers frame AstraZeneca
This snapshot was taken on 2026-09-29 across ChatGPT, Claude, Gemini, Perplexity and Grok, with 250 benchmark questions each. The questions never named a brand. AstraZeneca was named in 123 of 1,250 answers. Grok carried the most appearances (39 of 250), while the other four assistants each named it in 20 to 22. We read the 11 stored answers that named the company, a sample of those 123.
The context varied widely. In oncology pipeline questions, ChatGPT and Gemini put AstraZeneca near the top of their lists. Gemini's answer tied it to a $2 billion equity investment in Summit Therapeutics. Claude's answer on inhaler costs named AstraZeneca as the only brand from this sector in its list of savings programs, citing $35 and $0 cards for specific products. Gemini and Perplexity placed it in corporate social responsibility and executive-pay-for-access answers, and Gemini listed it among companies whose executives testified to Congress on list prices in 2019.
The same name also appeared in risk-oriented answers. ChatGPT's answer on legal and regulatory risk for investors described AstraZeneca as dealing with pricing and market-access disputes, including 340B enforcement actions. Claude and Grok named it in Phase 3 failure questions. Grok listed a terminated lung cancer trial, a cardiovascular outcomes study and a breast cancer trial that missed statistical significance on progression-free survival.
By question intent, visibility was highest on sustainability (28%) and leadership (21%), then clinical outcomes (15%) and innovation (12%). It was 0% on value and service, 4% on reliability and 2% on safety. The few classified credits were small: Financial Performance (3), Sustainability & Ethics (2), and single credits for Safety & Compliance and Price & Value.
AstraZeneca is frequently cited as a leader in the "targeted revolution" of cancer care.
What the press is saying
The PeakMetrics news index recorded 12,060 mentions of AstraZeneca in the last 30 days, 1,605 of them with the company in the headline. The five recent headlines supplied are about business activity: a global license agreement for an oral EGFR inhibitor for lung cancer, an after-hours share surge tied to a $2 billion equity deal with Summit, a growth-stock comparison with Amgen, a new hypertension drug registered in Russia, and an AI-assisted breast cancer diagnostic tool introduced in Malaysia.
Among sector peers, several large pharma names show higher news counts, including Merck at 20,731, Eli Lilly at 19,681 and Pfizer at 19,027. Several show higher answer counts too, including Johnson & Johnson at 192 of 1,250 and Pfizer at 174. AstraZeneca sits in the middle of the group on both measures in this snapshot.
Multiple reported Phase 3 issues, including termination of a volrustomig (PD-1/CTLA-4 bispecific) trial in lung cancer…
The gap
The press headlines supplied are transactional: licensing, equity stakes, stock comparisons and market launches. The assistants drew on a different set of themes. They reached for pipeline depth, patient savings cards, access-to-medicines work, congressional hearings, 340B disputes and Phase 3 outcomes. Only the Summit deal appears on both sides, in the recent headlines and in Gemini's oncology answer.
Sustainability and leadership questions produced the most visibility, while value, service, reliability and safety produced almost none. The subjects where the assistants were most likely to name AstraZeneca are not the subjects of the five headlines supplied. Those headlines are a small slice of the coverage, so this is a contrast of themes, not a claim about all press.
What to watch
Trial-outcome and legal-risk questions are where the assistants named AstraZeneca alongside setbacks. Grok's answer cited specific trial names and outlets such as BioPharma Dive and STAT. A comms team can check which sources feed those answers and whether the company's own trial and regulatory disclosures appear among them.
Some answers rely on older material. Gemini's congressional answer cites a 2019 hearing, and the sustainability answers lean on index rankings. Because live answers vary between runs, these are single-snapshot readings. Repeat the benchmark questions before treating any pattern as stable.